[1] Xiao M, Sun ZY, Kang M, et al. Five-year national surveillance of invasive candidiasis:species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study[J]. J Clin Microbiol,2018, 56(7):e00577-18.
[2] Sharma SV, Lee DY, Li B,et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J]. Cell, 2010, 141(1):69-80.
[3] Morschhäuser J. Regulation of multidrug resistance in pathogenic fungi[J]. Fungal Genet Biol, 2010,47(2):94-106.
[4] Smith WL,Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals:correlation with reduction in CDR and ERG upregulation[J]. Antimicrob Agents Chemother, 2002, 46(11):3532-3539.
[5] Li X, Cai Q, Mei H, et al. The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans[J]. J Antimicrob Chemother, 2015, 70(7):1993-2003.
[6] Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts:Approved Standard M27-A3[S]. CLSI, Wayne, PA, USA, 2008.
[7] Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts:Fourth Informational Supplement M27-S4[S]. CLSI, Wayne, PA, USA, 2012.
[8] Suzuki MM, Bird A. DNA methylation landscapes:provocative insights from epigenomics[J]. Nat Rev Genet, 2008, 9(6):465-476.
[9] Yang XJ,Seto E. The Rpd3/Hda1 family of lysine deacetylases:from bacteria and yeast to mice and men[J]. Nat Rev Mol Cell Biol, 2008, 9(3):206-218.
[10] Chung CG,Poligone B. Cutaneous T cell lymphoma:an update on pathogenesis and systemic therapy[J]. Curr Hematol Malig Rep, 2015, 10(4):468-476.
[11] Li Y, Chen K, Zhou Y, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor[J]. Curr Cancer Drug Targets, 2015, 15(6):493-503.
[12] Pfaller MA, Messer SA, Georgopapadakou N,et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens[J]. J Clin Microbiol, 2009, 47(12):3797-3804.
[13] Prince HM, Dickinson M,Khot A. Romidepsin for cutaneous T-cell lymphoma[J]. Future Oncol, 2013, 9(12):1819-1827.
[14] Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma:prolonged stable disease provides clinical benefits for patients in the pivotal trial[J]. J Hematol Oncol, 2017, 10(1):154.
[15] Furumai R, Matsuyama A, Kobashi N, et al. FK228(depsipeptide) as a natural prodrug that inhibits class I histone deacetylases[J]. Cancer Res, 2002, 62(17):4916-4921.